- Conditions
- Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Oligoastrocytoma
- Interventions
- Carboplatin, Etoposide, Etoposide Phosphate, Laboratory Biomarker Analysis, Mannitol, Melphalan, Quality-of-Life Assessment, Sodium Thiosulfate
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2021
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 339
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
- Interventions
- Armodafinil, placebo
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- irinotecan hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Interventions
- monoclonal antibody Me1-14 F(ab')2
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2001
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
- Interventions
- Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Winston-Salem, North Carolina
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma
- Interventions
- enzastaurin hydrochloride
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 8
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma
- Interventions
- oncolytic HSV-1716, dexamethasone, therapeutic conventional surgery, laboratory biomarker analysis
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma, IDH-Wildtype, Malignant Glioma
- Interventions
- Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab, Tumor Resection
- Procedure · Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma Multiforme, Astrocytoma, Grade III, Astrocytoma, Grade IV, Brain Cancer
- Interventions
- Neural stem cells loaded with an oncolytic adenovirus
- Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Duarte, California • Chicago, Illinois
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- O6-benzylguanine, carmustine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 51
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 40 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- chemotherapy, suramin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 15 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2004
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Extra-adrenal Paraganglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Interventions
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
- Conditions
- Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma, Recurrent Glioma
- Interventions
- Niraparib
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- carboplatin, tamoxifen citrate, topotecan hydrochloride, pharmacological study
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Brain Cancer, Glioblastoma Multiforme
- Interventions
- Vorinostat, Erlotinib, Temozolomide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, Imaging biomarker analysis, Photon Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
- Interventions
- Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID, High-dose OKN-007, TID
- Drug
- Lead sponsor
- Oblato, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Louisville, Kentucky • Winston-Salem, North Carolina + 1 more
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- cyproheptadine hydrochloride, megestrol acetate
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 40
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
- Conditions
- Brain Cancer, MALIGNANT GLIOMA, Glioblastoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Anaplastic Oligo-astrocytoma (AOA), Anaplastic Mixed Gliomas, Malignant Glioma NOS
- Interventions
- Bevacizumab & Stereotactic Radiotherapy
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 5
- States / cities
- San Francisco, California • Basking Ridge, New Jersey • Commack, New York + 2 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide
- Drug
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 10
- States / cities
- Stanford, California • Miami Beach, Florida • Chicago, Illinois + 7 more
- Conditions
- Childhood Brain Tumors
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carmustine, polifeprosan 20 with carmustine implant, surgical procedure
- Drug · Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Durham, North Carolina